{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:27:47Z","timestamp":1781033267866,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Following an acute ischemic stroke (AIS), rapidly initiated reperfusion therapies [i. e., intravenous thrombolysis (IVT) and endovascular treatment (EVT)] demonstrate robust clinical efficacy. However, only a subset of these patients can benefit from these therapies due to their short treatment windows and potential complications. In addition, many patients despite successful reperfusion still have unfavorable outcomes. Thus, neuroprotection strategies are urgently needed for AIS patients. Chlorpromazine and promethazine (C+P) have been employed in clinical practice for antipsychotic and sedative purposes. A clinical study has also shown a neuroprotective effect of C+P on patients with cerebral hemorrhage and subarachnoid hemorrhage. The safety, feasibility, and preliminary efficacy of intravenous administration of C+P in AIS patients within 24 h of onset will be elucidated.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A prospective randomized controlled trial is proposed with AIS patients. Participants will be randomly allocated to an intervention group and a control group with a 1:1 ratio (<jats:italic>n<\/jats:italic> = 30) and will be treated with standard therapies according to the current stroke guidelines. Participants allocated to the intervention group will receive intravenous administration of C+P (chlorpromazine 50 mg and promethazine 50 mg) within 24 h of symptom onset. The primary outcome is safety (mainly hypotension), while the secondary outcomes include changes in functional outcome and infarction volume.<\/jats:p><jats:p><jats:bold>Discussions:<\/jats:bold> This study on Rapid Intervention of Chlorpromazine and Promethazine for Hibernation-like Effect in Stroke (RICHES) will be the first prospective randomized controlled trial to ascertain the safety, feasibility, and preliminary efficacy of intravenous C+P as a neuroprotection strategy in AIS patients. These results will provide parameters for future studies, provide insights into treatment effects, and neuroprotection with phenothiazine in AIS.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>www.chictr.org.cn<\/jats:ext-link>, identifier: ChiCTR2000038727.<\/jats:p>","DOI":"10.3389\/fneur.2021.621476","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T05:55:10Z","timestamp":1615960510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Rapid Intervention of Chlorpromazine and Promethazine for Hibernation-Like Effect in Stroke: Rationale, Design, and Protocol for a Prospective Randomized Controlled Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuyu","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary B.","family":"Rajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitu","family":"Dandu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1474-4422(18)30500-3","article-title":"Stroke in China: advances and challenges in epidemiology, prevention, and management","volume":"18","author":"Wu","year":"2019","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/01616412.2019.1603592","article-title":"From big data to battling disease: notes from the frontiers of cerebrovascular science","volume":"41","author":"Stone","year":"2019","journal-title":"Neurol Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/svn-2017-000074","article-title":"The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke","volume":"2","author":"Dong","year":"2017","journal-title":"Stroke Vasc Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/bc.bc_36_18","article-title":"Treatment for ischemic stroke: from thrombolysis to thrombectomy and remaining challenges","volume":"5","author":"Leng","year":"2019","journal-title":"Brain Circ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s0891-5849(01)00628-1","article-title":"Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neurodegenerative diseases","volume":"31","author":"Drew","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/j.1471-4159.2007.04675.x","article-title":"Central nervous system regulation of mammalian hibernation: implications for metabolic suppression and ischemia tolerance","volume":"102","author":"Drew","year":"2007","journal-title":"J Neurochem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbpb.2012.01.008","article-title":"Neuroprotection: lessons from hibernators","volume":"162","author":"Dave","year":"2012","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.pneurobio.2016.03.002","article-title":"Hibernation-like neuroprotection in stroke by attenuating brain metabolic dysfunction","volume":"157","author":"Forreider","year":"2017","journal-title":"Prog Neurobiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History of the discovery and clinical introduction of chlorpromazine","volume":"17","author":"Lopez-Munoz","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.pra.0000351878.45260.94","article-title":"Use and safety of antipsychotic drugs during pregnancy","volume":"15","author":"Einarson","year":"2009","journal-title":"J Psychiatr Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1345\/aph.1H241","article-title":"Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients","volume":"40","author":"Lacasse","year":"2006","journal-title":"Ann Pharmacother"},{"key":"B13","first-page":"146","article-title":"Artificial hibernation therapy for cerebral hemorrhage","volume":"3","year":"1960","journal-title":"Chin J Neuropsychol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.23736\/S0390-5616.19.04665-4","article-title":"Low dose concomitant treatment with chlorpromazine and promethazine is safe in acute ischemic stroke","volume":"63","author":"Zhu","year":"2019","journal-title":"J Neurosurg Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1007\/s12035-016-0280-x","article-title":"Neuroprotection by chlorpromazine and promethazine in severe transient and permanent ischemic stroke","volume":"54","author":"Geng","year":"2017","journal-title":"Mol Neurobiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/1567202616666190624122727","article-title":"Artificial hibernation by phenothiazines: a potential neuroprotective therapy against cerebral inflammation in stroke","volume":"16","author":"Guan","year":"2019","journal-title":"Curr Neurovasc Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/brainsci9120378","article-title":"Reduced apoptotic injury by phenothiazine in ischemic stroke through the NOX-Akt\/PKC pathway","volume":"9","author":"Tong","year":"2019","journal-title":"Brain Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/0963689718819443","article-title":"Therapeutic target and cell-signal communication of chlorpromazine and promethazine in attenuating blood-brain barrier disruption after ischemic stroke","volume":"28","author":"Li","year":"2019","journal-title":"Cell Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa1414792","article-title":"Endovascular therapy for ischemic stroke with perfusion-imaging selection","volume":"372","author":"Campbell","year":"2015","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A randomized trial of intraarterial treatment for acute ischemic stroke","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"B22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","year":"2008","journal-title":"Res Nurs Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1545968309331863","article-title":"Progressive staging of pilot studies to improve phase III trials for motor interventions","volume":"23","author":"Dobkin","year":"2009","journal-title":"Neurorehabil Neural Repair"},{"key":"B24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fneur.2020.00313","article-title":"Remote ischemic conditioning for intracerebral hemorrhage (RICH-1): rationale and study protocol for a pilot open-label randomized controlled trial","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.14336\/AD.2019.0330","article-title":"Novel insights on systemic and brain aging, stroke, amyotrophic lateral sclerosis, and Alzheimer's disease","volume":"10","author":"Shetty","year":"2019","journal-title":"Aging Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14336\/AD.2018.0205","article-title":"Increased inflammatory response in old mice is associated with more severe neuronal injury at the acute stage of ischemic stroke","volume":"10","author":"Shen","year":"2019","journal-title":"Aging Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1747-4949.2011.00596.x","article-title":"Early neurological deterioration (END) after stroke: the END depends on the definition","volume":"6","author":"Siegler","year":"2011","journal-title":"Int J Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/bc.bc_58_19","article-title":"Multiphase adjuvant neuroprotection: a novel paradigm for improving acute ischemic stroke outcomes","volume":"6","author":"Zhao","year":"2020","journal-title":"Brain Circ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/bc.bc_5_19","article-title":"Therapeutic hypothermia: applications in adults with acute ischemic stroke","volume":"5","author":"Kuczynski","year":"2019","journal-title":"Brain Circ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/01616412.2019.1609160","article-title":"Clinical potential of pre-reperfusion hypothermia in ischemic injury","volume":"41","author":"Han","year":"2019","journal-title":"Neurol Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-7091-6391-7_9","article-title":"Neuroprotective strategies in nature\u2013novel clues for the treatment of stroke and trauma","volume":"73","author":"Frerichs","year":"1999","journal-title":"Acta Neurochir Suppl"},{"key":"B33","first-page":"539","article-title":"Prevention by chlorpromazine of ischemic liver cell death","volume":"88","author":"Chien","year":"1977","journal-title":"Am J Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/0090-4295(85)90495-9","article-title":"Effects of chlorpromazine on ischemic rat kidney: a functional and ultrastructural study","volume":"25","author":"Jayachandran","year":"1985","journal-title":"Urology"},{"key":"B35","first-page":"827","article-title":"The protective action of chlorpromazine on the spinal cord of rabbits submitted to ischemia and reperfusion is dose-dependent","volume":"43","author":"Sader","year":"2002","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0006-8993(89)90560-x","article-title":"Phenothiazines reduce ischemic damage to the central nervous system","volume":"482","author":"Zivin","year":"1989","journal-title":"Brain Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/neu.1989.6.153","article-title":"Chlorpromazine protects rat spinal cord against contusion injury","volume":"6","author":"Sadanaga","year":"1989","journal-title":"J Neurotrauma"},{"key":"B38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1179\/1743132815Y.0000000031","article-title":"Enhanced beneficial effects of mild hypothermia by phenothiazine drugs in stroke therapy","volume":"37","author":"Liu","year":"2015","journal-title":"Neurol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejphar.2014.04.017","article-title":"Chlorpromazine confers neuroprotection against brain ischemia by activating BKCa channel","volume":"735","author":"Li","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neulet.2014.10.037","article-title":"The antioxidative, non-psychoactive tricyclic phenothiazine reduces brain damage after experimental traumatic brain injury in mice","volume":"584","author":"Songarj","year":"2015","journal-title":"Neurosci Lett"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.621476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T05:55:14Z","timestamp":1615960514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.621476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":40,"alternative-id":["10.3389\/fneur.2021.621476"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.621476","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"article-number":"621476"}}